Why healthcare, why now?

Policy clarity, solid fundamentals, and attractive valuations

On Tuesday, September 30, the pharmaceutical industry issued its first formal response to President Trump’s recent letter on drug pricing, announcing a deal between Pfizer and the US administration. The outcome is favourable for biopharma, biotechnology, and related life science sectors, with equity markets reacting positively.

The healthcare sector is now trading near 35-year lows in relative valuations, while its weight in the S&P 500 has fallen to a 24-year low. This creates meaningful room for sustained momentum in a sector that remains heavily under-owned.

With that announcement the overhangs for the sector are now largely cleared. A short recap:

  • The U.S Food and Drug administration (FDA )remains operational during the shutdown.
  • M&A activity is strong and in our view, likely to accelerate.
  • Interest rates are trending lower.
  • Tariff risks are being reduced by manufacturer commitments to invest in the US.
  • The Pfizer–US administration drug pricing agreement offers a workable template for the industry.

 

We believe these developments provide an interesting entry point for healthcare strategies, with investor focus shifting back to fundamentals. 

In biotechnology, we see the beginning of a new growth cycle, as a wave of mid-cap companies approaches large-cap scale. Oncology remains well-positioned to benefit from regulatory momentum, with exposure across pharma, biotech, and life science tools and services — the “picks and shovels” of biomedical research.

Appendix Pfizer

For those who want to go into the details, please find some background on the Pfizer deal.

In late July, President Trump’s letter to pharmaceutical companies requested:

  • Most Favoured Nation (MFN) pricing for Medicaid.
  • MFN pricing guarantees for newly launched drugs.
  • Repatriation of international revenues to benefit American patients and taxpayers.
  • Direct purchasing at MFN pricing levels.


The financial effect is negligible:

  • Medicaid exposure is limited and already subject to steep discounts.
  • Most drugs will still flow through insurers, not direct consumer purchases.
  • For new launches, ex-US markets must either accept higher pricing or risk delayed access.
  • Importantly, this removes significant overhangs: pricing risk and tariff discussions are now largely off the table.


Where do we go from here?
Negotiations are ongoing with the broader sector, with Eli Lilly likely to be the next mover.

  • Companies with larger Medicaid exposure could face a marginally greater impact. However, Medicaid pricing is already heavily discounted, limiting the downside.
  • Sector-wide, this marks a decisive positive catalyst, reducing regulatory uncertainty and improving visibility.

[1] A new government-run website with Pfizer as its first partner, offering select drugs at discounts direct to consumer.

What makes today an interesting time for investing in Healthcare?

Hear from our experts why healthcare stocks are back to steady growth after the post-Covid reset. Demographic tailwinds and forecasts of further rate cuts, combined with good clinical data, should further support the sector’s performance.

Latest analyses

  • ESG, SRI

    Why healthcare, why now?

    On Tuesday, September 30, the pharmaceutical industry issued its first formal response to President Trump’s recent letter on drug pricing, announcing a deal between Pfizer and the US administration.
  • ESG, SRI, Oncology

    From uncertainty to growth: why invest in healthcare?

    As we enter the month of October, investors are faced with an obvious question: is the time right for new investments in the oncology sector? Pasquale Sansone, Senior Biotechnology Analyst, shares his analysis and convictions.
  • Ken Van Weyenberg, Oncology, ESG, SRI

    Why oncology remains a key investment opportunity

    The investment landscape is marked by persistent macroeconomic uncertainties, uneven growth, and heightened geopolitical risks. Despite attractive earnings growth, healthcare has also been under pressure due to regulatory restructuring, drug pricing debates, budget constraints, and tariff concerns.
  • Research Paper, Climate Action, ESG, SRI, Alix Chosson

    Net Zero Progress Report

    We promised you transparency. For a comprehensive discussion of our efforts and results, see our [annual] Net Zero Progress Report 2024. We frequently say that it is not just the carbon target, but the path to that target which affects the damage along the way. In this spirit, we share with you along the way our milestones for the four pillars of our Net Zero strategy.
  • ESG, SRI

    Active Ownership: Persistence Pays

    If some elements of our annual 2024 Annual Engagement and Voting Review sound familiar, that’s no coincidence. To maximize our impact, we focus on long-term core topics. Engagement and voting are central to our investment process, extending beyond the important responsibility of the investments we already hold.
  • Research Paper, Marie Niemczyk, Jorick Liebrand, ESG, SRI, AI

    AI Through the ESG Lens: Tackling Risks and Opportunities

    Is the Artificial Intelligence (AI) revolution unstoppable? With lightning speed, AI is reshaping industries, unlocking economic value, driving positive environmental impact, helping address social challenges – and additionally, offering compelling investment opportunities.
  • Philippe Dehoux, Lucia Meloni, Fixed Income, ESG, SRI, Climate Action, Biodiversity, Water, Sovereign Sustainability

    Generating Impact in the Bond Space – But How?

    Impact investments have kept rising over the past decades, reaching $1.6 trillion USD according to the Global Impact Investing Network (GIIN) – that is $ 1.6 trillion USD in assets allocated toward solutions supporting the Sustainable Development Goals.

Find it fast

Get information faster with a single click

Get insights straight to your inbox